Presentation is loading. Please wait.

Presentation is loading. Please wait.

E1308: A Phase II Trial of Induction Chemotherapy Followed by Cetuximab with Low Dose vs. Standard Dose IMRT in Patients with HPV-Associated Resectable.

Similar presentations


Presentation on theme: "E1308: A Phase II Trial of Induction Chemotherapy Followed by Cetuximab with Low Dose vs. Standard Dose IMRT in Patients with HPV-Associated Resectable."— Presentation transcript:

1 E1308: A Phase II Trial of Induction Chemotherapy Followed by Cetuximab with Low Dose vs. Standard Dose IMRT in Patients with HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

2 Disclosures Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

3 Slide 3 Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

4 Background: HPV+ OP SCCa Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

5 Rationale: Cetuximab based Induction CT Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

6 Slide 6 Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

7 Endpoints Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

8 Statistics Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

9 Results Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

10 Slide 10 Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

11 Results: Acute Toxicity Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

12 Late Toxicity Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

13 Response: Induction Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

14 Response: Following Cetux/IMRT Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

15 Endpoint: 2yr PFS and OS Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

16 PFS and Survival: Dose Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

17 Low Dose: T stage and N stage Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

18 Smoking: PFS and Survival Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

19 Best Outcome:

20 First Failure Patterns: Low-dose pts Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

21 Summary Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

22 Conclusions Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

23 Designed and conducted by: Presented By Anthony Cmelak at 2014 ASCO Annual Meeting


Download ppt "E1308: A Phase II Trial of Induction Chemotherapy Followed by Cetuximab with Low Dose vs. Standard Dose IMRT in Patients with HPV-Associated Resectable."

Similar presentations


Ads by Google